APG Asset Management N.V. Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• APG Asset Management N.V. has reduced its stake in Regeneron Pharmaceuticals by 5.3%, now owning approximately 0.07% of the company, valued at $45.4 million.
• In the last quarter, Regeneron Pharmaceuticals reported an earnings per share (EPS) of $12.89, exceeding analyst expectations of $8.43, with revenue increasing 3.6% year-over-year.
• The firm announced a quarterly dividend of $0.88 to be paid on September 3rd, representing a 0.6% yield based on the current valuation.

APG Asset Management N.V. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 77,407 shares of the biopharmaceutical company's stock after selling 4,348 shares during the period. APG Asset Management N.V. owned 0.07% of Regeneron Pharmaceuticals worth $45,449,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of REGN. GAMMA Investing LLC raised its position in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the period. Nuveen LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at $343,764,000. Pacer Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after buying an additional 303,785 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Regeneron Pharmaceuticals by 30.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after buying an additional 226,952 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent research reports. Morgan Stanley reiterated an "overweight" rating and issued a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Jefferies Financial Group raised their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Citigroup reissued a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $0.08 during midday trading on Friday, reaching $579.53. The company had a trading volume of 197,975 shares, compared to its average volume of 1,101,583. The business's 50-day simple moving average is $555.84 and its 200 day simple moving average is $588.67. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,210.97. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a market cap of $61.42 billion, a P/E ratio of 14.61, a P/E/G ratio of 1.96 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company's revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company earned $11.56 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.